Cancer Targeted Drug Delivery

A Time Travel Journey Through Cancer Therapies.- Nanotechnology for Cancer Treatment: Possibilities & Limitations.- Vascular Targeting Approaches to Treat Cancer.- Tumor Immunotherapy by Utilizing a Double-Edged Sword Chemokines.- Cancer Biology: Some Causes for a Variety of Different Diseases.- Cancer Stromal Targeting (CAST) Therapy and Tailored Antibody Drug Conjugate Therapy Depending on Nature of Tumor Stroma.- Cancer Cell Respiration: Hypoxia and pH in Solid Tumors.- Tumor Vasculature, EPR Effect, and Anticancer Nanomedicine: Connecting the Dots.- Pressure Gradients in Solid Tumors.- The ADAMs: New Therapeutic Targets for Cancer?.- Role of the Extracellular Matrix - Enzyme Activities and Metastasis.- The Role of Non-Cancerous Cells in Cancer: Pancreatic Ductal Adenocarcinoma as Model to Understand the Impact of Tumor Microenvironment on Epithelial Carcinogenesis.- Heterogeneity of Cancers and its Implication for Targeted Drug Delivery.- A Study of Cancer Heterogeneity: From Genetic Instability to Epigenetic Diversity in Colorectal Cancer.- Nanotherapeutics in Multidrug Resistance.- Stem Cells and Cancer.- Mechanisms of Metastasis.- Cancer-Specific Ligand/Receptor Interactions.- Targeting Drugs to Cancer: A Tough Journey to the Tumor Cell.- Long Circulation and Tumor Accumulation.- Convective and Diffusive Transport in Drug Delivery.- Intravital Real-Time Confocal Laser Scanning Microscopy for the in Situ Evaluation of Nanocarriers.- The EPR effect in Cancer Therapy.- In Vitro 3-dimensional Cancer Culture Model.- Complex Transport Around Tumor: Need for Realistic In Vitro Tumor Transport Model.- The Missing Components Today and the New Treatments Tomorrow.

Professor You Han Bae

Professor You Han Bae received his Ph.D. in 1988 from University of Utah. He has background of chemical engineering and polymer science/engineering and pharmaceutical chemistry. He served University of Utah as a postdoctoral fellow and research assistant/associate professor till 1994. He joined the Department of Materials Science and Engineering at Gwangju Institute of Science and Technology (GIST) in Korea in 1994 as an associate professor and promoted to a full Professor in 1998. After serving 7.5 years at GIST, he came back to the University of Utah as a full professor in 2002.

He researched stimuli sensitive polymers and drug delivery, protein drug stabilization and controlled release, and functionalized polymers for glucose sensor and biohybrid artificial pancreas. His current research interests include nanoparticulates for multidrug resistance in cancer and tumor heterogeneity, novel carrier design for the delivery of genetic materials and preclinical cancer models. He is the author or co-author of over 240 peer-reviewed scientific papers, book chapters and U.S. Patents which have been cited more than 14,000 times.

He is an editorial board member of Pharmaceutical Research and Bioconjugate, and is also currently serving the Journal of Controlled Release (JCR) as an America Associate Editor as well as the Editor of the Concept Paper in JCR.





Professor Randall Mrsny